Systemic aspergillosis caused by an aflatoxin-producing strain of Aspergillus flavus

Medical Mycology

Volumn 36, Issue 2, 1998, Pages 107-112

  Mori, T ^a   Matsumura, M ^a   Yamada, K ^a   Irie, S ^a   Oshimi, K ^a   Suda, K ^b   Oguri, T ^c   Ichinoe, M ^d  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c University Hospital   (Japan)

^d TOKYO KASEI UNIVERSITY   (Japan)

Author keywords

Aflatoxin; Aspergillus flavus; Bone marrow transplantation; High performance liquid chromatography

Indexed keywords

AFLATOXIN;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; BONE MARROW TRANSPLANTATION; CASE REPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MORTALITY; MYCOSIS; NEUTROPENIA; PROGNOSIS; REMISSION; STRAIN DIFFERENCE;

ADULT; AFLATOXINS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FLAVUS; BONE MARROW TRANSPLANTATION; FATAL OUTCOME; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LUNG; LUNG DISEASES, FUNGAL; MALE; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031835049     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-280X.1998.00124.x     Document Type: Article

References (29)

1. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillus: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147-201.
2. Denning DW. Therapeutic outcome in invasive aspergillus. Clin Infect Dis 1996; 23: 608-15.
3. Obayashi T, Yoshida M, Mori T, et al. Plasma (1 → 3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard M27-P. Villanova, PA: National Committee for Clinical Laboratory Standards, 1992.
5. Golas CL, Prober CG, MacLeod SM, Soldin SJ. Measurement of amphotericin B in serum or plasma by high-performance liquid chromatography. J Chromatogr 1983; 278: 387-95.
6. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole; an overview. Mycoses 1989; 32 (Suppl. 1): 67-87.
7. 1 by Aspergillus flavus in a semisynthetic medium. Appl Microbiol 1966; 14: 378-80.
8. 2 production by a human pathogenic strain of Aspergillus flavus. Mycologia 1981; 73: 697-704.
9. Schindler AF, Palmer JG, Eisenberg WV. Aflatoxin production by Aspergillus flavus as related to various temperatures. Appl Microbiol 1967; 15: 1006-9.
10. Joffe AZ, Lisker N. Effects of light, temperature, and pH value on aflatoxin production in vitro. Appl Microbiol 1969; 18: 517-18.
11. Oyelami OA, Maxwell SM, Adelusola KA, Aladekoma TA, Oyelese AO. Aflatoxins in the autopsy brain tissue of children in Nigeria. Mycopathologia 1995; 132: 35-8.
12. Shank RC, Bourgeois CH, Keschamras N, Chandavimol P. Aflatoxins in autopsy specimens from Thai children with an acute disease of unknown aetiology. Fd Cosmet Toxicol 1971; 9: 501-7.
13. Krishnamachari KAVR, Bhat RV, Nagarajan V, Tilak TBG. Hepatitis due to aflatoxicosis; an outbreak in western India. Lancet 1975; 1-2: 1061-3.
14. 1 in human tissues with high-pressure liquid chromatography. Toxicol Appl Pharmacol 1981; 58: 422-30.
15. Kok WT. Derivatization reactions for the determination of aflatoxins by liquid chromatography with fluorescence detection. J Chromatogr B 1994; 659: 127-37.
16. Polak A. Combination therapy with antifungal drugs. Mycoses 1988; 31 (Suppl.): 45-53.
17. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 1995; 39: 1779-83.
18. Pier AC. Mycotoxin and animal health. Adv Vet Sci Comp Med 1981; 25: 185-243.
19. Denning DW. Aflatoxin and human disease. Adv Drug React Ac Pois Rev 1987; 4: 175-209.
20. Takahashi T. Distribution and characteristics of aflatoxin-producing Aspergillus flavus in the soil in Kanagawa prefecture, central Japan. Mycopathologia 1993; 121: 169-73.
21. Pier AC, Belden EL, Ellis JA, Nelson EW, Maki LR. Effects of cyclopiazonic acid and aflatoxin singly and in combination on selected clinical, pathological and immunological responses of guinea pigs. Mycopathologia 1989; 105: 135-42.
22. Pier AC. Major biological consequences of alfatoxicosis in animal production. J Anim Sci 1992; 70: 3964-7.
23. Hall AJ, Wild CP. Aflatoxin biomarkers. Lancet 1992; 339: 1413-14.
24. Hendrickse RG. Kwashiorkor: the hypothesis that incriminates aflatoxins. Paediatrics 1991; 88: 376-9.
25. Ross RK, Yuan J-M, Yu MC, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-6.
26. 1-guanine adduct and heptatis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res 1987; 47: 3430-3.
27. 1 and T-2 toxin on the granulocyte-macrophage progenitor cells in mouse bone marrow cultures. Immunopharmacology 1994; 27: 57-65.
28. Jakab GJ, Hmieleski RR, Zarba A, Hemenway DR, Groopman JD. Respiratory aflatoxicosis: suppression of pulmonary and systemic host defenses in rats and mice. Toxicol Appl Pharmacol 1994; 125: 198-205.
29. Tang CM, Cohen J, Krausz T, Van Noorden S, Holden DW. The alkaline protease of Aspergillus fumigatus is not a virulence determinant in two murine models of invasive pulmonary aspergillosis. Infect Immun 1993; 61: 1650-6.